INTRODUCTION
Biosimilars are biopharmaceuticals that are approved by a regulatory agency and are highly similar to an approved marketed biologic product [1] [2] [3] . There is strong interest throughout the world in developing biosimilars to many currently marketed biopharmaceuticals, with the hope of reduced costs for medical care coupled with increased accessibility to these medicines.
Many countries, including those in the European Union (EU) and the United States (US), have created abbreviated approval pathways for biosimilars (compared with the requirements for innovative molecules) that require a comparison of the proposed biosimilar with the approved product, generally termed the reference product, to demonstrate biosimilarity. The EU defines the reference product as the product that has been granted marketing authorization in the EU [1] .
In a similar manner, the US Biologics Price Competition and Innovation Act defines the reference product as the US Food and Drug Administration (FDA)-licensed product [2] .
Under certain circumstances, both the European Medicines Agency (EMA) and FDA allow the use of data derived from human or animal studies comparing a proposed biosimilar to a reference product licensed in another region that has scientific and regulatory standards compatible with the International Conference on Harmonization [2, 4] . arthritis, and plaque psoriasis [5] . The Fc region of infliximab is human, while the Fv region with the complementarity determining region (CDR) that binds human tumor necrosis factor alpha (TNF) is derived from the mouse.
Infliximab binds soluble and transmembrane human TNF and blocks its interaction with p55 and p75 cell surface TNF receptors, thereby neutralizing the proinflammatory effects of TNF [6] . A number of nonclinical in vivo studies were conducted during the development of infliximab. These included single-and repeat-dose (up to five doses) studies in chimpanzees, single-and repeat-dose (up to seven doses) studies in rats, and a local tolerance study in rabbits [7] . Nonclinical toxicity studies were conducted primarily in chimpanzees because infliximab neutralizes human and chimpanzee TNF with similar potency. Infliximab does not have activity against mouse, rat, rabbit, pig, cotton top tamarin, marmoset (species not identified), pigtail macaque, rhesus monkey, cynomolgus monkey, or baboon TNF [7] . Although weak activity against dog TNF was observed (0.01% of potency for human or chimpanzee TNF), nonclinical testing of infliximab in this species was discontinued because immediate dermal hypersensitivity (urticaria and angioedema) was observed with the initial intravenous (IV) infusion [7] . In rats, minimal and reversible hepatic changes (Kupffer cell and hepatocellular hyperplasia) and slight reductions in erythrocyte counts, hemoglobin levels, and hematocrit values were observed after single or repeat daily doses at C10 mg/kg/day, but these findings were not considered relevant to humans, because they were considered to be related to the response of a normal rat reticuloendothelial system to large doses of chimeric (human-mouse) antibody, a foreign protein to this test animal [8] . Infliximab was well tolerated in chimpanzees, rabbits, and rats. Additional studies were conducted in mice using a surrogate anti-mouse TNF mAb that was reported to have similar pharmacodynamic and pharmacokinetic properties as infliximab [7] . No adverse infliximab surrogate-related findings were observed in 6-month repeat-dose or developmental and reproductive toxicity studies in mice using the surrogate anti-mouse TNF mAb up to 40 mg/kg [7] .
PF-06438179 is an anti-TNF mAb currently under development as a potential biosimilar to
Remicade. Consistent with current regulatory authority guidelines [1] [2] [3] , a stepwise approach was used during development, whereby PF-06438179 was first evaluated for structural and functional similarity to the reference product in vitro. These analytical studies of PF-06438179 were performed side by side with Remicade sourced from the US (infliximab-US) [5] and the EU (infliximab-EU) [9] . Key attributes of primary structure, post-translational modifications, product purity, charge heterogeneity, and biological activity were shown to be similar [10] . Based on the comparative structural and functional results providing strong support for analytical similarity, of which only a small subset is outlined in this nonclinical paper, ProteinSimple iCE 280 system. The CBP enzyme was used to cleave the C-terminal lysine from the sample by incubating the mixture for 1 h at 25°C.
Size Exclusion HPLC Native PF-06438179, infliximab-EU, and infliximab-US samples were fractionated using a dihydroxypropane bonded silica column (8 mm 9 300 mm; Waters YMC-Pack Diol-200) at 30°C and a salt containing mobile phase at pH 5.0. The analysis was performed using isocratic flow conditions, and the absorbance was monitored at 280 nm using a Waters-2695 Alliance HPLC system equipped with an ultraviolet detector.
Biological Activity
Using an in-house validated assay, a serial dilution of each PF-06438179, infliximab-EU, and infliximab-US sample was prepared and incubated for 35 min at 37°C and 5% carbon dioxide with recombinant human TNF (R&D Systems). Then, the content of each incubation was added to a 96-well plate containing U937 
In Vivo Animal Studies
The single-and repeat-dose studies were conducted in Sprague-Dawley (Crl:CD
Ò
[SD]) rats (Charles River Laboratories). All rats were acclimated to the laboratory environment for a minimum of 14 (single-dose study) or 13 (repeat-dose study) days prior to initiation of dosing. The IV route was chosen because it is consistent with the intended clinical route of administration and was used during the nonclinical program of infliximab. Toxicokinetic (TK) parameters were calculated from individual animal data using noncompartmental analysis (Watson LIMS, version 7.4.1; Thermo Inc). TK parameters included C max , time to C max , and AUC. Samples tested below the limit of quantification (\0.1 lg/mL in 100% serum) were assigned a value of 0 lg/mL for the TK calculations.
Single-Dose Study TK and Tolerability Study Comparing PF-06438179 with Infliximab-EU in Rats The objective of this study was to determine the TK and tolerability of PF-06438179 compared with infliximab-EU when administered as a single dose to male rats (aged 9-10 weeks and weight at dose initiation, 337.9-392.6 g).
PF-06438179
or infliximab-EU was administered by single IV bolus injection (volume of 5 mL/kg) to male rats (n = 5/group) at doses of 10 or 50 mg/kg. A separate group of five male rats received vehicle #1, and another group of five male rats received vehicle #2. Vehicles #1 and #2 consisted of excipients and buffers identical to those used with PF-06438179 and infliximab-EU, respectively, but with no active protein. 
Compliance with Ethics Guidelines
In vivo animal studies were conducted in 
RESULTS

Characterization Assessments
Peptide Mapping Using LC/MS
The chromatographic profiles for PF-06438179, infliximab-US, and infliximab-EU were essentially superimposable (Fig. 1) . predominant N-glycopeptides were G0F and G1F. For PF-06438179, the predominant C-terminal form of the heavy chain was des-lysine; however, for infliximab-US and infliximab-EU, the predominant C-terminal form was lysine. Minor modifications such as heterogeneity of C-terminal lysine are not expected to be clinically significant [11] and, therefore, were not considered to impact similarity [10] . The essentially superimposable chromatographic profiles of PF-06438179 against the reference products and consistent peak-by-peak peptide identifications by MS The iCE profile consistently had three regions: acidic, main, and basic. The relative content of basic isoforms of PF-06438179 was less than that observed for the reference products (Fig. 3) .
The basic region primarily contained two peaks, which correlate to the presence of C-terminal lysine residues on the heavy chains. The two basic peaks were suspected to be mono-C-terminal lysine and di-C-terminal lysine species. This is consistent with the heavy chain C-terminal lysine observed by peptide map and subunit analyses. To confirm that the difference in the relative proportion of basic species between PF-06438179 and the reference products was related solely to C-terminal lysine, the materials were treated with carboxypeptidase B (CBP). The carboxypeptidase cleaves C-terminal lysine from the three materials, resulting in iCE profiles representative of the remaining charge heterogeneity. After treatment with CBP, the iCE profiles for PF-06438179 and two reference products were similar (Fig. 4) , as were the relative abundance of acidic, main, and basic species (Table 1) .
Size Exclusion HPLC
The size exclusion HPLC profile had consistently two peaks: high-molecular mass species (HMMS) and monomer. Low-molecular mass peaks were occasionally observed in the reference product, but levels were just above the 
Biological Activity
The functional similarity of PF-06438179, infliximab-US, and infliximab-EU was assessed by determining the ability of each to inhibit TNF-induced apoptosis in the U937 cell line, a human monocyte cell line that expresses TNF receptors. In this assay, PF-06438179 binds specifically to soluble TNF and blocks its interaction with cell surface TNF receptors on the U937 cell, thereby inhibiting TNF-induced apoptosis. The dose-response curves of (Fig. 6 ), demonstrating functional similarity in their ability to bind TNF. Multiple lots of PF-06438179 and reference products had similar relative potencies (data not shown).
In Vivo Rat Studies
Based on the structural and functional similarity between PF-06438179, infliximab-US, and infliximab-EU, as demonstrated in the in vitro characterization assessments, limited in vivo studies were conducted in Sprague-Dawley rats.
A comparative single-dose TK and tolerability study with PF-06438179 and one reference product (infliximab-EU) was conducted initially. A 2-week IV toxicity study was conducted later in the program based on a were similar to infliximab-EU at each dose following a single IV dose of 10 or 50 mg/kg (Fig. 7) . Systemic exposure, as assessed by C max and area under the concentration-time curve (AUC) in the PF-06438179 and infliximab-EU groups, were similar and increased with increasing dose (Table 1) . Mean systemic exposure ratios C max and AUC 1344 and AUC inf , respectively, ranged between 0.88 and 1.16 for PF-06438179 relative to infliximab-EU (Table 2) Table 4 ). Because of its minimal-to-mild severity and the lack of other effects on the liver, this change was not considered adverse.
There were no consistent sex-related differences in systemic exposure [as assessed by C max and AUC at 168 h (AUC 168 )]; therefore, group mean TK parameters are discussed and presented using combined data from both male and female rats within each dose group. Mean systemic exposure increased with increasing dose in an approximately dose proportional manner on days 1 and 8 (Table 5) . Mean systemic exposure (AUC 168 ) was higher on day 8 relative to day 1, with day 8:day 1 exposure ratios of 1.7 and 1.6 at the 10 and 50 mg/kg doses, respectively. There was no suggestion of ADA based on consistent serum concentrations of PF-06438179 throughout the study.
Following once-weekly IV administration of PF-06438179, 50 mg/kg was identified as the no-observed adverse-effect level (NOAEL) based on lack of adverse findings in any in-life or postmortem evaluations in this 2-week toxicity study in rats. At this dose, the combined male and female C max was 1360 lg/mL and the AUC 168 was 115,000 lg h/mL on day 8 (Table 5) . Table 2 Toxicokinetic parameters of PF-06438179 compared with infliximab-EU: a single-dose study 
DISCUSSION
In vitro analytical characterization, of which only a small subset is presented in this study, demonstrated that the proposed biosimilar, PF-06438179, is structurally and functionally similar to its reference products, infliximab-US and infliximab-EU, and that the reference products are similar to each other. Peptide mapping and subunit analyses confirmed that PF-06438179 has the identical primary structure as that of the reference product infliximab.
Peptide mapping, subunit analysis, and iCE focusing confirmed that PF-06438179 has post-translational modifications similar to those of the reference products, with the exception of the levels of C-terminal lysine.
This is a minor difference that is not expected to be clinically significant because the C-terminal lysine is rapidly processed in vivo with a half-life of 62 min [10, 11] . Size exclusion HPLC confirmed PF-06438179 has a product profile and a purity similar to those of the reference products. In the biological activity assay, PF-06438179 bound TNF, thus inhibiting because no sex differences in TK were observed with the originator infliximab in rats [17] . In addition, there were no major weight-, age-, or sex-related differences in clearance or volume of distribution of infliximab in patients [5] . 9. The use of only the EU-approved product (infliximab-EU) as the comparator in the TK/tolerability study was considered reasonable because the in vitro assays demonstrated that infliximab-licensed products sourced from the US or EU were similar to each other. However, because pharmaceutical companies are seeking to develop biosimilar drug products globally, the overall program must meet the requirements of all countries where trials and registration are planned. During additional regulatory interactions, a 2-week toxicity study with PF-06438179 in both sexes was requested before clinical trials could proceed in one country/region. Based on this request, a 2-week IV toxicity study with PF-06438179 in male and female rats was conducted.
In the 2-week toxicity study in rats, once-weekly IV (bolus) administration of 10 or 50 mg/kg doses of PF-06438179 produced no adverse findings in any parameters evaluated. PF-06438179-related microscopic findings were limited to minimal to mild sinusoidal cell hyperplasia in the liver in both males and females administered 50 mg/kg. This finding was not adverse because of the minimal to mild severity and lack of other effects on the liver.
The sinusoidal cell hyperplasia observed in this study was consistent with Kupffer cell hyperplasia observed in previous studies in rats following IV administration of Remicade at either single daily doses C10 mg/kg, or at seven daily doses C10 mg/kg/day [8] 
